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Abstract  23 
All members of the Caliciviridae family of viruses produce a subgenomic 24 
RNA during infection. The subgenomic RNA typically encodes only the major and 25 
minor capsid proteins, but in murine norovirus (MNV), the subgenomic RNA also 26 
encodes the VF1 protein that functions to suppress host innate immune 27 
responses. To date, the mechanism of norovirus subgenomic RNA synthesis has 28 
not been characterized. We have previously described the presence of an 29 
evolutionarily conserved RNA stem-loop structure on the negative-sense RNA, 30 
the complementary sequence of which codes for the viral RNA-dependent RNA 31 
polymerase (NS7). The conserved stem-loop is positioned 6 nucleotides 3’ of the 32 
start site of the subgenomic RNA in all caliciviruses. We demonstrate that the 33 
conserved stem-loop is essential for MNV viability. Mutant MNV RNAs with 34 
substitutions in the stem-loop replicated poorly until they accumulated mutations 35 
that revert to restore the stem-loop sequence and/or structure. The stem-loop 36 
sequence functions in a non-coding context as it was possible to restore the 37 
replication of a MNV mutant by introducing an additional copy of the stem-loop 38 
between the NS7 and VP1 coding regions. Finally, in vitro biochemical data 39 
would suggest that stem-loop sequence is sufficient for the initiation of viral RNA 40 
synthesis by the recombinant MNV RdRp, confirming that the stem-loop forms 41 





Noroviruses are a significant cause of viral gastroenteritis and it is 46 
important to understand the mechanism of norovirus RNA synthesis. Herein we 47 
describe the identification of an RNA stem-loop structure that functions as the 48 
core of the norovirus subgenomic RNA promoter in cells and in vitro. This work 49 
provides new insights into the molecular mechanisms of norovirus RNA synthesis 50 
and the sequences that determine the recognition of viral RNA by the RNA 51 
dependent RNA polymerase. 52 
 53 
  54 
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Introduction 55 
Noroviruses, members of the Caliciviridae family of small positive-sense 56 
RNA viruses are a major cause of viral gastroenteritis in the developed world (1, 57 
2). Despite their impact, noroviruses remain poorly characterized as an in-depth 58 
understanding of the molecular mechanisms of norovirus genome translation and 59 
replication have been hampered by the inability to culture human norovirus (3). 60 
Murine norovirus (MNV) is a model system with which to understand the 61 
norovirus life cycle (4) as it replicates in cultured cells (5) and a number of 62 
tractable reverse genetics systems are available (6-9). Studies of MNV have 63 
therefore led to a number of significant advances in the understanding of the 64 
molecular mechanism of norovirus genome translation and replication (Reviewed 65 
in 10). 66 
 67 
The norovirus RNA genome typically encodes three open reading frames 68 
(11). MNV also encodes an additional ORF in the region overlapping the VP1 69 
coding region (12, 13) (Fig. 1A). All members of the Caliciviridae family of small 70 
positive-sense RNA viruses synthesize a shorter than genome length, 71 
subgenomic, RNA (sgRNA) which directs the translation of the major and minor 72 
structural proteins, VP1 and VP2 respectively (10). The MNV sgRNA also 73 
encodes the VF1 protein, an antagonist of the innate immune response (12). 74 
Production of a sgRNA during the viral life cycle is a common feature of many 75 
positive-sense RNA viruses (14) and it is often used to control the expression of 76 
the viral proteins.  77 
 5
 The mechanism of calicivirus sgRNA synthesis is not well-understood. 78 
Initial in vitro biochemical approaches using rabbit hemorrhagic disease virus 79 
(RHDV) suggested that a sequence upstream of the first nucleotide of the 80 
subgenomic RNA is required for sgRNA synthesis (15). This sequence acts in 81 
the complement of the RHDV genomic RNA. Bioinformatic analysis also 82 
confirmed the presence of evolutionarily conserved and stable RNA stem-loop 83 
structures upstream of the start of the sgRNA of caliciviruses (16).  Within the 84 
region coding for the viral RNA-dependent RNA polymerase (NS7, RdRp) in all 85 
caliciviruses analyzed, a ~24-50 nt stem-loop structure could be predicted on the 86 
negative-sense genomic RNA, precisely 6 nt 3’ of the sgRNA start site. This 87 
stem-loop structure in the MNV minus-strand RNA will be referred to as Sla5045 88 
(for stem-loop anti-sense 5045). We previously observed that the stable structure 89 
of Sla5045 is essential for the recovery of viable MNV in cultured cells (16). In 90 
the current study we present results consistent with the hypothesis that Sla5045 91 
forms the core of the norovirus sgRNA promoter. 92 
 93 
 94 
Materials and Methods 95 
Cell lines and plasmid constructs. The murine leukemia macrophage cell line 96 
(RAW264.7) was grown and maintained in Dulbecco modified Eagle medium 97 
(DMEM; Gibco) with 10% (v/v) fetal calf serum (FCS), penicillin (100 SI units/ml) 98 
and streptomycin (100 µg/ml) and 10 mM HEPES buffer (pH 7.6). Baby hamster 99 
kidney cells (BHK-21) engineered to express T7 RNA polymerase (BSR-T7 cells, 100 
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obtained from Karl-Klaus Conzelmann, Ludwig Maximillian University, Munich, 101 
Germany) were maintained in DMEM containing 10% FCS, penicillin (100 SI 102 
units/ml), streptomycin (100 µg/ml) and 1.0 mg/ml geneticin (G418). All cells 103 
were maintained at 37oC with 10% CO2.  104 
The full length MNV-1 cDNA clone, pT7:MNV3’Rz, contains the MNV-1 105 
genome under the control of truncated T7 polymerase promoter (7). Mutant 106 
derivatives of pT7:MNV3’RZ were made as previously describe (7, 16). These 107 
include: (i) a frameshift in the NS7 region of ORF1 (pT7:MNV 3’Rz F/S), (ii) the 108 
m53 mutations to destabilize the Sla5045 (pT7:MNVm53 3’Rz) and (iii) the m53r 109 
mutations to restore the Sla5045 (pT7:MNVm53r 3’Rz). Other full length MNV-1 110 
cDNA clones carrying m53 mutant suppressors (m53SupA, m53SupG and 111 
m53SupH) in m53 backbone construct were generated by overlapping PCR 112 
mutagenesis using pT7:MNVm53 3’Rz as a template.  All primer sequences used 113 
in this work and protocols will be made available upon request. Mutant 114 
suppressors were also engineered into pT7:MNV3’Rz, producing WTSupA, 115 
WTSupB and WTSupC cDNA constructs.  Additional synonymous mutations at 116 
position 4922 in the WT and m53 cDNA constructs with adenyltate and guanylate 117 
substitutions were also generated by overlapping mutagenesis PCR. The 118 
luciferase reporter-expressing MNV replicons used in this study were as reported 119 
previously (17). Briefly, the luciferase gene was fused to VP2 in the WT, POLFS, 120 
m53 and m53r constructs and separated by the foot and mouth disease virus 2A 121 
protease (FMDV 2A). The expression of luciferase reporter gene in these 122 
constructs is under the control of the MNV TURBS sequence (18, 19). 123 
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Translation of the luciferase reporter protein occurs as a VP2 fusion protein and 124 
is co-translationally cleaved at the specific FMDV 2A cleavage site to release 125 
both luciferase-2A and VP2.  126 
 Sla5045Dup contains a second copy of the WT or m53 stem-loop (Sla2) 127 
inserted outside of the NS7 coding region in the intergenic region between Orf1 128 
and Orf2 was used to generate constructs WT/WT, WT/m53, m53/WT and 129 
m53/m53 by overlapping PCR mutagenesis. A second panel of Sla5045Dup 130 
mutant constructs was also generated based on the m53/WT construct as 131 
detailed in the text.  132 
 133 
Reverse genetics and virus yield determination. Recoveries of full-length 134 
infectious MNV-1 cDNA clones were performed using the established reverse 135 
genetics system (7). Typically, BSR-T7 cells were infected with fowlpox virus 136 
expressing T7 RNA polymerase at a multiplicitiy of infection (MOI) of 0.5 plaque 137 
forming units (PFU) per cell before transfection with 1 µg of cDNA was carried 138 
out using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 139 
instructions. Note that the levels of T7 RNA polymerase normally expressed in 140 
BSR-T7 cells are not sufficient to drive MNV recovery.  Where indicated, the 141 
RNA-mediated reverse genetics system was used.  In this case, RNA transcripts 142 
were produced using in vitro transcription reactions which consisted of 200 mM 143 
HEPES pH7.5, 32 mM magnesium acetate, 40 mM DTT, 2 mM spermidine, 7.5 144 
mM of each NTP (ATP, UTP, GTP and CTP), 40 unit of RNAse inhibitor 145 
(Promega), 250 ng of linearized DNA template and 50 μg/ml of T7 RNA 146 
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polymerase. The reactions were incubated at 37°C for 2-7 h, treated with DNase 147 
I (New England Biolabs) and the RNA was purified by precipitation using lithium 148 
chloride and resuspended in RNA storage solution (Ambion) (9). Prior to 149 
transfection into BSR-T7 cells, post-transcriptional enzymatic capping was 150 
performed on the purified RNA transcripts using a ScriptCap system (Epicentre), 151 
according to manufacturers instructions. Typically one microgram of capped RNA 152 
was transfected using Lipofectamine 2000 according to the manufacturers’ 153 
instructions. The yield of infectious was determined 24 h post transfection of 154 
cDNA or capped RNA, using 50% tissue culture infectious dose (TCID50). Note 155 
that BSR-T7 cells, a BHK cell derivative can support only a single cycle of virus 156 
replication, possible due to the lack of a suitable receptor for virus reinfection.  157 
 158 
RNA purification and genome copy determination. All RNA purifications from 159 
infected and transfected cells were performed using the GenElute Mammalian 160 
Total RNA Miniprep Kit (Sigma Aldrich) according to the manufacturer’s 161 
instructions. RNA was quantified by spectrophotometry and qualitatively 162 
inspected by on agarose gels stained with ethidium bromide.   163 
 164 
The expression level of genomic RNA for WT and m53SupA MNV were 165 
quantified using one step RT-qPCR. Viral genome copies were determined using 166 
the MESA Blue qPCR Assay (Eurogentech) performed in parallel with control 167 
RNAs of known concentration using the primers 404F 168 
(GGAGCCTGTGATCGGCTCTATCTTGGAGCAGG) and 491R 169 
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(GCCTGGCAGACCGCAGCACTGGGGTTGTTGACC) to amplify the viral 170 
genomic RNA. 171 
Where described, strand-specific RT-qPCR was performed using tagged 172 
RT primers to detect either positive or negative-sense genomic RNA as 173 
previously described (20). In addition, a set of primers was designed to amplify 174 
nucleotides 5473-5422 to facilitate the simultaneous quantification of both 175 
genomic and subgenomic RNAs. Control RNAs for the genomic or subgenomic 176 
RNAs, of positive or negative-sense polarity, were generated by in vitro 177 
transcription and used as standards to facilitate quantification. 178 
 179 
Western blotting. Samples for western blot analysis were obtained by lysing 180 
cells in radioimmunoprecipitation assay buffer (RIPA - 50 mM Tris–HCl pH 8.0, 181 
150 mM NaCl, 1 mM EDTA, 1% Triton X-100 and 0.1% SDS). Protein 182 
concentration in the lysates were quantified using the bicinchoninic acid (BCA) 183 
protein assay (Pierce). Equal amounts of protein per samples were separated by 184 
SDS-PAGE  were transferred to a polyvinylidene fluoride (PVDF) Immobilon-P 185 
transfer membrane (Millipore) for detection using Enhance Chemiluminescence 186 
(ECL) reagents by semi-dry transfer. The blocking buffer (PBST) contained 0.1% 187 
Tween 20 in PBS containing 5% w/v milk powder and the rabbit anti-MNV NS7 or 188 
VP1 serum. Antibody binding was detected using a secondary, horseradish 189 
peroxidase-conjugated secondary antibody (source). The signal was detected by 190 
enhanced chemiluminescence kit (ECL; Amersham Biosciences). 191 
 192 
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Luciferase reporter assay. Cell lysates used to detect luciferase activity were 193 
prepared by lysing the transfected cells in 1 X Reporter Lysis Buffer (Promega) 194 
according to the manufacturers instructions. The protein concentration in each 195 
lysates was standardized  and total protein (30 μg) from each cell lysate was 196 
analyzed. The luciferase assays used a 1:500 dilution of coelentrazine 197 
(Promega) in PBS as a substrate. Luciferase activity was measured in an auto-198 
injector luminometer (FLUOstar Omega, BMG Labtech).  199 
 200 
Northern blot assay. Total RNAs were purified from infected cells and 201 
denatured by glyoxylation according to the manufacturers instructions (Ambion). 202 
Denatured RNAs along with the relevant control RNA generated by in vitro 203 
transcription to produce full-length MNV genomic and subgenomic RNAs of both 204 
polarities, were separated by agarose electrophoresis. Denatured RNAs were 205 
transferred to Hybond N+ nylon membranes using mild alkaline conditions and 206 
the viral RNA detected using the NorthernMax northern blotting system (Life 207 
Technologies). RNA probes used to detect the positive and negative-sense viral 208 
RNAs were generated by incorporating 32P-UTP or CTP using the Maxiscript in 209 
vitro labeling system, according to the manufacturer’s instructions (Ambion). The 210 
RNA probe used to detect the negative-sense viral RNA consisted of nts 1-200 of 211 
the positive sense sgRNA, whereas the positive sense viral RNA was detected 212 
using a probe complementary to nts 7161-7382. 213 
 214 
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5’ rapid amplification of cDNA ends (RACE). Total RNA preparations were 215 
subjected to cDNA synthesis using a reverse primer complementary to 216 
sequences ~700 bases downstream (on positive polarity) of Sla5045. The 217 
resulting cDNAs were treated with ribonuclease to degrade the viral RNA 218 
template prior. The purified cDNAs were then used as a template for RACE 219 
assay using 5’ RACE according to the manufacturer’s instructions (Life 220 
Technologies). Purified cDNAs were first subjected to the 3’ end poly(C) tailing 221 
reaction catalyzed by terminal transferase followed by PCR using an anchor 222 
primer that anneals to the poly(C) 3’end of cDNA and the MNV specific reverse 223 
primer. Sequences of the PCR products were determined using the BigDye 224 
terminator kit and analyzed using the Vector NTI software (Invitrogen). 225 
 226 
Primer extension analysis. Primer extension analysis was performed on RNA 227 
isolated from either infected cells or cells transfected with in vitro transcribed 228 
capped RNAs generated from MNV cDNA containing clones. The 33P γ-ATP 229 
labeled primer 5129R (GGTTGAATGGGGACGGCCTGTTCAACGG) was 230 
annealed to 10μg of total RNA was and extended using Superscript III according 231 
to the manufacturers’ instructions (Life Technologies). Reactions were stopped 232 
by the addition of formamide containing dye followed by separation on 6% urea-233 
PAGE. The extended products were visualized following exposure to 234 
autoradiography film and compared to samples isolated form infected cells and 235 
control RNA produced by in vitro transcription. 236 
 237 
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Recombinant RdRp expression and purification.  The cDNA encoding MNV 238 
NS7 (nts 3537 to 5069) was subcloned in pET-15b. The construct contains an N-239 
terminal six-histidine tag to facilitate protein purification. The plasmid expressing 240 
MNV NS7 was transformed into E. coli Rosetta cells, which were grown at 37°C 241 
until the optical density at OD600 was between 0.6 and 0.8. 242 
Isoproplythiogalactoside was added to a final concentration of 1 mM induce 243 
protein expression for 16-18 h at 16°C. The cells were harvested by 244 
centrifugation and resuspended in 40 ml lysis buffer (100 mM TrisCl, pH7.9, 300 245 
mM NaCl, 10% glycerol, 15 mM imidazole, 5 mM β-mercaptoethanol, 0.1% Triton 246 
X-100, protease inhibitor cocktail (Sigma). The recombinant protein was purified 247 
by Ni-NTA (Qiagen) according to the manufacturer’s instructions. The elute 248 
protein was dialyzed in buffer containing 100 mM TrisCl, pH 7.9, 300 mM NaCl, 249 
10% glycerol, 5 mM β-mercaptoethanol and stored in aliquots at -80oC.  250 
Recombinant GII.4 NS7 was expressed and purified as previously 251 
described (17). Briefly, E. coli Top 10 cells transformed with pBAD GII.4NS7 252 
plasmid were cultured at 37°C until an OD600 of around 0.6 was reached. L-253 
arabinose was added to a final concentration of 0.02% to induce protein 254 
expression. The cells were grown at 37°C for 5 h and then harvested and 255 
suspended in lysis buffer (50 mM HEPES pH 7.9, 150 mM NaCl, 10% glycerol, 256 
10 mM Imidazole, proteinase inhibitor cocktail (Sigma)). The protein was purified 257 
by Talon metal affinity resin (Clontech Laboratories) and the elute protein 258 
dialyzed in buffer containing 100 mM TrisCl, pH 7.9, 300 mM NaCl, 10% glycerol, 259 
5 mM β-mercaptoethanol and stored in aliquots at -80oC. All recombinant 260 
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proteins were quantified by using the Bradford method followed SDS-PAGE and 261 
staining with Coomassie brilliant blue to examine their purity. 262 
 263 
RNA synthesis assay.  RNA synthesis by the recombinant RdRps was assayed 264 
as previously described (21) with minor modifications. The 20 μl reaction 265 
contained 20 mM sodium glutamate (pH 7.4), 12.5 mM dithiothreitol, 4 mM 266 
MgCl2, 1 mM MnCl2, 0.5% Triton X-100 (v/v), 0.2 mM GTP, 0.1 mM ATP and 267 
UTP, 3.3 nM α-32P-CTP (MP Biomedicals), 50 nM MNV RNA template, 25 nM 268 
recombinant RdRp. The reaction was incubated at 30°C for 2 h, and then 269 
stopped by the addition of EDTA (pH 8.0) to final concentration of 10 mM.  The 270 
RdRp products were subjected to electrophoresis in 24% polyacrylamide gel 271 
containing 7.5 M urea and 0.5X TBE.  The radiolabeled RNA products were 272 
visualized and quantified by using a PhosphoImager (Typhoon 9210; Amersham 273 
Biosciences) and ImageQuant software.   274 
 275 
Results 276 
The stability of Sla5045 contributes to norovirus infectivity and 277 
subgenomic RNA synthesis. 278 
 Sequence analyses of published noroviruses genomes indicate that the 279 
stem-loop sequence of Sla5045 is highly conserved (data not shown and Fig. 280 
1B). Several positions in the Genogroup II (GII) or V (GV), representing human 281 
and murine noroviruses respectively, appear to show some variation in 282 
sequence, although in all cases a complex stem-loop structure is retained (Fig. 283 
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1B).  We initially sought to test the functional significance of the stability of 284 
Sla5045. Three nucleotide substitutions were introduced to the MNV genome, 285 
resulting in a construct named m53 (Fig. 1C). M53 was previously shown to have 286 
a severely reduced recovery of infectious virus (16). However, it was not 287 
determined whether the inability to produce detectable virus was due to a defect 288 
in RNA encapsidation or sgRNA production, or both. To further validate the role 289 
of Sla5045 in the norovirus life cycle and to examine whether the m53 mutations 290 
affect viral RNA synthesis, we inserted the previously described m53 291 
substitutions into the MNV luciferase replicon, Mflc-R (17). The replicon consists 292 
of a full-length MNV genome expressing a Renilla luciferase-FMDV 2A peptide-293 
VP2 fusion protein in the VP2 coding region. Transfection of BSRT7 cells with 294 
enzymatically capped, in vitro transcribed RNA from the Mflc-R cDNA leads to 295 
luciferase expression in the absence of infectious virus production. As luciferase 296 
is expressed from ORF3 and occurs via a conserved termination-reinitiation 297 
mechanism of translation at the translational termination signal of ORF2 (18, 19), 298 
it functions as a highly sensitive marker for the production of sgRNA. The 299 
introduction of the m53 mutations resulted in luciferase levels similar to a 300 
replication-defective replicon containing a frame-shift in the NS7 coding region 301 
(Fig. 1D). A construct containing compensatory mutations to m53, named m53r 302 
(Fig. 1C), that restored the stability of Sla5045 was found to restore luciferase 303 
expression levels to nearly the level of the WT MNV replicon (Fig. 1D). The 304 
introduction of m53r mutations also resulted in the recovery of infectious virus 305 
(Fig. 1E). These data are consistent with the hypothesis that Sla5045 plays a role 306 
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in viral RNA synthesis and does not simply affect a late stage in the viral life 307 
cycle such as encapsidation.  308 
 309 
 We analyzed the production of sgRNA in cells transfected with capped 310 
RNAs of m53 and m53r using a primer extension assay. A radiolabelled primer 311 
complementary to nucleotides 5121-5129 was annealed to RNA isolated from 312 
transfected cells and extended using reverse transcriptase, generating a product 313 
of 105 nts corresponding to the start of the sgRNA. Whilst sgRNA was detected 314 
in infected or cells transfected with WT RNA, it was absent in m53 but restored to 315 
almost wild-type levels in the m53r (Fig. 1F). Taken together, these data confirm 316 
that the stability of Sla5045 contributes to MNV sgRNA synthesis, as well as that 317 
the production of luciferase and the presence of infectious virus correlate with 318 
sgRNA synthesis. 319 
 320 
Rapid reversion and suppression of Sla5045 disruption occur in cell 321 
culture. 322 
The replication cycle of many positive-sense RNA viruses are error-prone 323 
and the reversion or phenotypic suppression of the introduced mutations can 324 
occur even during low levels of viral replication. Such reversion or suppression 325 
can become apparent after repeated passage of samples obtained by reverse 326 
genetics recovery. To examine whether it was possible to isolate revertants or 327 
suppressors of MNV containing the m53 mutations, named MNVm53, clarified 328 
tissue culture supernatants from three independent reverse genetics recoveries 329 
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were serially passaged in RAW264.7 cells until cytopathic effect (CPE) was 330 
observed. In all cases CPE was observed after 3 passages in permissive cells. 331 
Passages performed with similar samples obtained using the POLFS construct 332 
failed to result in CPE. Individual viral isolates were isolated by limiting dilution 333 
and the sequence of the NS7 coding region was determined. In all cases we 334 
observed additional changes either in Sla5045 or sequences elsewhere in the 335 
viral genome (Fig. 2). In total we identified 12 different independently-derived 336 
viable viruses that could be divided into two groups; phenotypic revertant 337 
mutants (Rev 1-9) that contained mutations that phenotypically restored the 338 
base-pairing of Sla5045 and suppressor mutants (Sup A-C) that retained the 339 
m53 mutations but had additional changes elsewhere. All Rev isolates contained 340 
mutations that appeared to restore the stability of Sla5045 by either reintroducing 341 
the WT sequence (Rev 2-6 and 8), or by introducing a stabilizing mutation on the 342 
opposite side of the stem (Fig. 2B). In contrast the suppressor mutants retained 343 
the m53 mutations but had additional changes in the NS7-coding region. Of the 344 
three Sup mutations identified, SupA and Sup C had synonomous mutations that 345 
did not alter the corresponding amino acid (data not shown), while SupB resulted 346 
in a threonine to alanine substitution at residue 439 of NS7.   347 
 348 
Both coding and non-coding suppressor mutations in the NS7 coding 349 
region complement the defect in MNVm53 350 
To confirm that SupA-C can suppress the defect in MNVm53 replication, 351 
individual mutations were introduced into full-length cDNA clones from WT MNV 352 
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or m53 and the effect on virus recovery examined in BSRT7 cells. The BHK-353 
derived BSRT7 cells are permissive for viral replication but not viral infection, 354 
with the viral yields being indicative of a single cycle of viral replication (7). All 355 
three suppressor mutations were viable in the m53 background, confirming their 356 
ability to restore the replication defect of MNVm53 (Fig. 3A). SupA, with an 357 
A4922G substitution on the negative-sense RNA, was consistently better at 358 
restoring the replication defect of MNVm53 than the SupB or C. improving viral 359 
yields by more than 10-fold when compared to the virus with both the m53 and 360 
either the SupB or SupC mutations. All three Sup mutations were also viable in 361 
the WT cDNA background, with SupA producing viral yields that were 362 
comparable to WT MNV by 48 h after transfection (Fig. 3A and 3B). Sequence 363 
analysis indicated that all viruses were stable for at least three passages in cell 364 
culture (data not shown). Given that Sup A and C had synonomous mutations, 365 
these results strongly suggest that the suppression of the m53 defect acted on 366 
the viral RNA. 367 
 368 
The replication of MNVm53SupA was further characterized by one-step 369 
growth curve analysis (Fig. 3B-D). The production of infectious virus (Fig. 3B), 370 
viral protein (Fig. 3C) and viral RNA (Fig. 3D) were all reduced in MNVm53SupA 371 
when compared to WT MNV. The mutation introduced in SupA results in a silent 372 
U4922C mutation on the positive-sense RNA (Fig. 4A). This position 373 
corresponded to an alanine at codon 461 in NS7 and enables additional silent 374 
mutations to be introduced. We examined whether substitutions to the other 375 
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three nucleotides at this position would also suppress the m53 defect as well as 376 
affect WT MNV. All 4 mutations were well tolerated in a WT MNV background 377 
whereas only the substitutions equivalent to SupA, A4922G on the minus strand, 378 
or A4922U on the minus-strand RNA, restored replication in the MNVm53 379 
backbone (Fig. 4B). All viable viruses could be repeatedly passaged in cell 380 
culture and the sequences introduced remained stable (data not shown). These 381 
data suggest that there is a sequence specific requirement for the ability of 382 
position 4922 to suppress the defect in MNVm53. 383 
 384 
Sla5045 function at a different location in the MNV genome 385 
Due to the location of Sla5045 in the NS7 coding region, mutational 386 
analysis was limited to synonymous changes that do not alter the NS7 protein 387 
sequence. To facilitate additional mutational analysis, we added a second copy 388 
of Sla5045, named Sla2, after the ORF1 termination codon. Sla2 is located within 389 
a noncoding intragenic region introduced between the coding sequence of NS7 390 
and VP1 in construct Sla5054Dup (Fig. 5A). The cDNA of Sla5045Dup was 391 
engineered to contain either a WT or m53 version of Sla5045 or in the region 392 
containing Sla2. In vitro transcribed and capped RNA was then transfected into 393 
cells and the effect on virus yield examined 24 hours post transfection. RNA-394 
mediated reverse genetics recovery was used to significantly improve the yield of 395 
recovered viruses and to enhance our ability to detect viruses that replicate 396 
poorly.  As expected, RNA generated from the WT MNV cDNA clone resulted in 397 
~105 infectious units per ml, whereas m53 and a polymerase mutant failed to 398 
 19
produce any detectable virus (Fig. 5B). Sla5045Dup containing Sla5045 WT/Sla2 399 
WT (WT/WT) reproducibly yielded viable virus whereas the WT/m53 construct, 400 
containing a mutated Sla2 did not (Fig. 5B). In constructs where Sla5045 401 
contained the m53 mutations, a WT Sla2 restored replication whereas a m53 402 
Sla2 did not (Fig. 5B). These results demonstrate that only stem-loop sequences 403 
positioned at Sla2 function as a sgRNA promoter in the context of the 404 
Sla5045Dup cDNA constructs. Importantly however, given that the yield of virus 405 
obtained from the Sla5045Dup constructs WT/WT and m53/WT was significantly 406 
lower than that of the WT virus (Fig. 5B), it appears that the sgRNA promoter 407 
functions less well in the Sla2 position. 408 
 409 
      Western blot analysis was used as an indirect measure of viral RNA 410 
transfection efficiency as we have previously observed that viral antigen 411 
expression after transfection of RNA is due to translation of the capped RNA only 412 
and not due to viral replication (9). Similar levels of the NS7 protein were 413 
detectable in all cases, although the Sla5045Dup construct that contained 414 
Sla5045 WT/Sla2 WT produced a protein detected by the anti-NS7 antisera with 415 
higher molecular weight (identified by an asterisk in Fig. 5B). We suspect that 416 
this was due to the insertion of an additional stable stem-loop structure in close 417 
proximity to the NS7 stop codon resulting in suppression of translational 418 
termination as this has been widely documented in the literature (Reviewed in 419 
22). This hypothesis is also supported by the absence of the extended product 420 
when the Sla5045 was disrupted by the introduction of the m53 mutations. The 421 
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lack of NS7 expression in the POLFS polymerase mutant was due to the 422 
introduction of a frame-shift mutation leading to the production of a truncated 423 
NS7 protein that is rapidly degraded (9). 424 
 425 
     Although the titers of the Sla5045Dup viruses recovered were low, some 426 
of the introduced mutations were stable and could be passaged in cell culture, 427 
indicating that they are viable (Fig. 5C). Sequence analysis and 5’ RACE 428 
confirmed that the introduced mutations were stable for up to 3 passages in cell 429 
culture and that the start of the sgRNA produced during authentic norovirus 430 
replication in cell culture is position 5052, as has been predicted previously (Fig. 431 
5D) (4). 432 
 433 
The sequence, positioning and stability of Sla5045 are essential for 434 
norovirus replication. 435 
Our data indicates that the Sla5045 is essential for norovirus replication 436 
and that its function can be complemented by an additional copy in cis in a non-437 
coding region upstream of the capsid-coding sequence. To examine the 438 
sequence requirement further we made constructs that contained a mutated m53 439 
within the NS7 coding region along with various mutant forms in the second copy 440 
present in the non-coding region. The construct Sla5045Dup m53/Sla2 m53r 441 
contained the m53r derivative of Sla5045 that is predicted to compensate for the 442 
disrupted base pairs in m53  (Fig. 6A). As expected, the Sla5045Dup m53/Sla2 443 
m53r produced viable virus after reverse genetics recovery (Fig. 6B). The 444 
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resultant virus could be passaged in cell culture (Fig. 6C) and that stably 445 
maintain both copies of Sla5045 (data not shown). In contrast Sla5045Dup 446 
m53/Sla2 WT+8, where the spacing between the stem-loop and the predicted 447 
initiation site of the sgRNA was increased from 6 to 8 nts was not viable. 448 
Significant alterations to the base stem sequences (Sla5045Dup m53/Sla2 SL+ 449 
or SL-) or disruption of the top stem sequence (Sla5045Dup m53/Sla2 S2) also 450 
prevented replication (Fig. 6A-C). In contrast, the introduction of two nucleotide 451 
changes in the terminal loop region of Sla5045 in the construct Sla5045Dup 452 
m53/Sla2 TL-Dis had no effect on the ability of Sla5045 to complement the defect 453 
in the m53 mutant backbone did not produce viable virus (Fig. 6A-C). 454 
 455 
Sla5045 functions as a template for the norovirus RNA polymerase NS7 in 456 
vitro. 457 
Results from characterization of Sla5045 are all consistent with the 458 
hypothesis that Sla5045 forms the core of the promoter for MNV sgRNA 459 
synthesis and is used to direct sgRNA synthesis. However, it is unclear whether 460 
it functions directly in RNA synthesis. To determine whether this is the case, we 461 
examined whether RNAs that contain Sla5054 can direct RNA-dependent RNA 462 
synthesis by the recombinant MNV NS7 protein in vitro (Fig. 7A). An RNA 463 
containing Sla5045 with a 5’ overhang that contains the initiation nucleotide 5052 464 
was chemically synthesized in a RNA we termed the MNV proscript, MNVps. The 465 
term proscript is used to denote that the RNA contains both a putative promoter 466 
and the template sequence (23) (Fig. 7B). Should the MNV proscript direct 467 
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accurate initiation of RNA synthesis from nt 5052, an 11-nt product should result. 468 
Based on comparison with RNAs of known lengths, the products of MNVps were 469 
11-nt in length. We also observed a 10-nt RNA that is presumed to be a 470 
premature termination product that has been previously observed with other 471 
recombinant RdRps. (Fig. 7C; 24). To ascertain that the RNA was initiated from 472 
the expected cytidylate at nt 5052, we tested an RNA that is identical to MNVps 473 
except that nt 5052 was substituted with an adenylate named IM.  IM failed to 474 
direct the synthesis of either the 10- and 11-nt RNA products (Fig. 7C). These 475 
data confirm that Sla5045 can accurately direct de novo initiation of the norovirus 476 
sgRNA synthesis.  477 
       In the in vitro RNA synthesis reactions we also detected an RdRp product 478 
of ca. 60-nt, longer in length than the input proscript. This RNA is likely formed by 479 
viral RdRp using the 3’ terminal nucleotide of the template RNA to form a primer-480 
extended product (25). This activity is common to numerous viral RdRps (26, 27). 481 
Notably, IM generated a higher abundance of the primer-extended RNA products 482 
than did MNVps. Since de novo initiated RNA product generated from MNVps 483 
was more abundant that those from primer extension, we conclude that the 484 
recombinant MNV RdRp has a propensity for de novo initiated RNA synthesis 485 
from the MNV sgRNA.  486 
      To examine further whether the MNV Sla5045 can direct a genotype-487 
specific RNA synthesis by the MNV RdRp, we performed in vitro RNA synthesis 488 
reaction with proscript containing the comparable sequence from a human GII.4 489 
norovirus named GII.4Ps (Fig. 7B). Accurate de novo initiated RNA synthesis 490 
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from GII.4Ps should give rise to an 8-nt product (Fig. 7D). The recombinant MNV 491 
RdRp did produce RNAs of 8-nt and a 7-nt from GII.4Ps (Fig. 7D). However, in 492 
more than six independent assays, the amount of the RNA product was 27% of 493 
the amount produced from the MNV RdRp. In contrast, the recombinant GII.4 494 
RdRp produced more than 30-fold the amount of products from the GII.4Ps than 495 
from the MNVps (Fig. 7D). The MNV RdRp reproducibly produced a reduced 496 
amount of the primer-extension product from the GII.4ps (13%, Fig. 7D). 497 
Furthermore, the GII.4 RdRp also produced a reduced level of primer-extension 498 
products from the MNVps  (Fig. 7D). These results suggest that MNV RdRp can 499 
specifically recognize the MNVps.  500 
 501 
Negative-sense subgenomic RNA is produced during MNV replication 502 
The presence of Sla5045 on the negative-sense genomic RNA and the 503 
ability of Sla5045 to function in vitro as a template for priming by the RdRp would 504 
fit with the hypothesis that MNV uses a process of internal initiation for the 505 
generation of sgRNA. However, negative-sense sgRNA is readily detected in 506 
cells infected with feline calicivirus (28) and in Norwalk replicon containing cells 507 
(29). Northern blot and strand-specific RT-qPCR analysis of RNA isolated from 508 
MNV infected cells also confirmed the presence of a negative-sense sgRNA 509 
intermediate (Fig. 8A). Whilst we observed similar levels of negative-sense 510 
genomic and sgRNA produced in infected cells, the levels of sgRNA were 511 
typically >26 fold higher than the genomic RNA levels (Fig. 8B), fitting with 512 
previous observation on FCV and Norwalk virus (28, 29). These data are 513 
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consistent with the hypothesis that newly synthesized MNV sgRNA may function 514 




In this study we used a combination of genetic and biochemical 519 
approaches to characterize a stem-loop RNA sequence that we predicted to be 520 
the MNV sgRNA promoter. A mutant MNV that has substitutions that disrupted 521 
the predicted secondary structure of the stem-loop was poorly infectious while 522 
nucleotide substitutions that restored the stem-loop structure allowed the virus to 523 
regain infectivity. Suppressor mutations found after repeated passages in cell 524 
culture also had restored Sla5045 structure, although additional suppressor 525 
mutants were also isolated outside of the Sla5045. Examination of a second copy 526 
of the sla5045 in a non-coding region of the MNV genome revealed that the 527 
stem-loop structure functions in cis. Using purified recombinant viral RdRp, we 528 
demonstrate an RNA containing Sla5054 can direct the genotype-specific initiate 529 
RNA synthesis from Sla5045.  530 
 531 
A change in the codon of viral RdRp NS7 was found in SupB, which 532 
suppressed the changes in m53. Further analysis of this nucleotide position 533 
indicated that the effect was mediated in a non-coding context as changing this 534 
codon (ACU) to GUU to code for valine, or to GAU to code for aspartic acid, also 535 
restored replication to the m53 (data not shown). There are several explanations 536 
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for our ability to isolate second site suppressor mutations outside of Sla5045; the 537 
first is that Sla5045 may form higher order RNA structures with other regions of 538 
the viral genome, including the positions identified as second site suppressors, 539 
and that the second site suppressors stabilize these interactions. Our 540 
bioinformatic analysis has failed to identify any obvious interactions between the 541 
regions (data not shown). However, accurate predictions of long- or medium-542 
range RNA-RNA interactions are not currently available and we cannot at this 543 
point rule out that long-range RNA-RNA interaction contribute to Sla5045 544 
function. In addition, the introduction of the m53 mutations could result in 545 
promiscuous base-pairing of Sla5045 with other sequences flanking the start of 546 
the sgRNA. The suppressor mutations then function to disrupt the ‘off-target’ 547 
RNA-RNA interactions, favoring the restoration of the Sla5045 structure.  548 
Distinguishing between these two possibilities will be challenging, however our 549 
observation that the addition of Sla5045 to the 3’ end of mini-genome RNA 550 
encoding a reporter gene in the antisense orientation is not sufficient to drive 551 
RNA synthesis and reporter gene expression in infected cells (data not shown), 552 
suggests that additional RNA sequences may contribute to RNA synthesis 553 
directed by core promoter that consists of Sla5045.  554 
 555 
The production of a sgRNA is conserved in all members of the 556 
Caliciviridae yet the mechanism of its synthesis is poorly understood. In contrast, 557 
the synthesis of sgRNA is well characterized in numerous other RNA viruses 558 
(Reviewed in 14). For viruses that possess only a single genomic RNA and 559 
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generate a single sgRNA, one commonly used mechanism for sgRNA synthesis 560 
is the premature termination of negative-strand RNA synthesis that is used by the 561 
viral replicase as a template to produce the positive-sense sgRNA. A hallmark of 562 
the premature termination mechanism is the production of a truncated negative-563 
sense sgRNA during virus replication. Low levels of negative-sense sgRNA have 564 
been identified in cells stably replicating the Norwalk virus replicon (29), in 565 
purified replication complex from feline calicivirus infected cells (28) and as now 566 
in MNV infected cells (Fig 8). However, our data and those from previous 567 
publications (15) would suggest an alternative model for MNV sgRNA synthesis. 568 
This mechanism is used by plant viruses (23, 30, 31) and alphaviruses (32, 33) 569 
and involves the binding of the viral replicase complex to a specific sequence 570 
and/or structure present in negative-sense genomic RNA. Our data is consistent 571 
with Sla5045 being required as an RNA structure needed for MNV infectivity and 572 
to function as a template for RNA synthesis by the RdRp.  It is also important to 573 
note that in the plant viruses, it is not clear which subunit(s) of the viral replicase 574 
can specifically recognized the sgRNA promoter and our results demonstrate that 575 
the norovirus RdRp is sufficient for recognition of the sgRNA core promoter. In 576 
addition we observed that a genotype-specific interaction between the RdRp and 577 
the subgenomic proscript affected the amount of RNA synthesis (Fig. 7D). Our 578 
data would however indicate that as negative-sense sgRNA is present in MNV 579 
infected cells, the newly synthesized MNV sgRNA may function as a template for 580 
additional rounds of RNA replication by the viral RdRp via a dsRNA intermediate. 581 
 27
The precise initiation site of the calicivirus sgRNA has been identified 582 
previously in a number of studies. The human norovirus sgRNA initiation site has 583 
been previously confirmed using a helper virus system to drive the production of 584 
viral genomic RNA in cells (34). In the related vesivirus FCV, 5’RACE was also 585 
used to identify the specific sgRNA initiation site (35). To our knowledge, our 586 
work provides the first confirmation of the start site of norovirus sgRNA during an 587 
authentic infectious norovirus replication cycle. 588 
 Our data would indicate that the positioning of the core sgRNA promoter is 589 
critical for its function as in the Sla5045Dup constructs, only the sgRNA promoter 590 
sequences in Sla2 region functioned (Fig. 5). In addition, increasing the distance 591 
between the stem-loop structure and the sgRNA initiation site from 6 to 8 nts, 592 
also debilitated virus replication (Fig. 6). These data are in agreement with our 593 
previous observations using bioinformatics analysis of all calicivirus genomes 594 
that indicate an absolute conservation of the spacing i.e. invariably 6 nts (16).  595 
 596 
Overall our data demonstrate that norovirus sgRNA synthesis relies on a 597 
sequence and genotype-specific interaction of the viral RdRp with a stem-loop 598 
sequence on the minus-strand RNA. These observations add to our growing 599 
understanding of the norovirus life cycle and the molecular mechanisms used by 600 
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Figure legends: 729 
 730 
Fig. 1. The stability of Sla5045 is required for norovirus infectivity, 731 
replication and sgRNA synthesis.  732 
A) A schematic of the murine norovirus (MNV) genome, highlighting the four 733 
open reading frames and Sla5045. B) Genetic conservation of the Sla5045 734 
sequences on the norovirus negative-sense viral RNA. The position of the 735 
potential norovirus subgenomic RNA initiation site is indicated with an arrow. The 736 
position of the VP1 initiation codon on the positive-sense RNA is highlighted in 737 
bold and sequence variation observed in different isolates is shown as bold italic 738 
text. Genogroup II noroviruses (GII); the sequence of the GII isolate 739 
Hu/GII.4/MD-2004/2004/US is shown (DQ658413) with variation between the 740 
following isolates shown: FJ595907.1, AB447425.1, HM635151, HM635164, 741 
JF262610.1 and JF262592. Genogroup V (GV) murine norovirus; the sequence 742 
of the CW1 isolate (DQ285629) is shown with variation between the following 743 
isolates displayed; JN975491 and JN975492. Note that for simplicity, only 744 
sequences showing variation in the stem-loop sequence were used in the 745 
analysis and shown in the figure. C) The structure of Sla5045 and the mutations 746 
introduced to generate the mutant m53 and m53r as described previously (16). In 747 
the case of m53r, the mutations shown are in addition to those present in m53. 748 
D) Luciferase replicon based analysis of the effect of Sla5045 disruption. 749 
Luciferase levels represent the mean of triplicate independent samples. E) Virus 750 
yield after reverse genetics recovery of full-length cDNA constructs containing 751 
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either MNV wild type (WT), a polymerase frame shift in the NS7 (POLFS), m53 or 752 
m53r. The virus titres represent the mean values obtained 24 hours post 753 
transfection of viral cDNA expression constructs. The detection limit of the assay 754 
is indicated with a dotted line. In all cases where shown, error bars represent the 755 
SEM. F) Primer extension-mediated detection of sgRNA synthesis in MNV 756 
infected cells (Inf) or cells transfected with capped RNAs of WT, POLFS, m53 or 757 
m53r clones. In vitro transcribed sgRNA is was used as a positive control 758 
(sgRNA) and produces a product 3 nts longer due to the addition of three 5’ G 759 
nts by T7 RNA polymerase. Note that 1000 fold less RNA was used for the 760 
reaction using RNA from infected cells. 761 
 762 
 763 
Fig. 2: Sequence analysis of m53 phenotypic revertants and second site 764 
suppressor mutants. 765 
A) Positions mutated in the m53 mutant are shown in bold, with the any changes 766 
observed in the phenotypic revertants highlighted in grey. The nucleotide 767 
sequences shown are for the negative-sense RNA genome. An asterisk indicates 768 
that the identified sequence change results in a coding change in the viral NS7 769 
protein (T439A). Revertant mutants are defined as those that phenotypically 770 
restore the base pairing of Sla5045. Suppressors are those that retain the 771 
mutations in Sla5045 but have additional mutations outside of the region.  B) 772 
Location of reversion mutations isolated after repeated passage of m53 in cell 773 
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culture. Note that the suppressor mutations are not shown as they lie outside of 774 
the region containing Sla5045. 775 
 776 
Fig. 3: Characterization of m53 suppressor mutations. 777 
A) Virus yield following reverse genetics rescue of cDNA constructs containing 778 
with WT or m53 MNV cDNA with or without the additional second site mutations 779 
as detailed in Table 1. Reverse genetics recovery was performed as described in 780 
the materials and methods then the virus yield at 24 hours post transfection 781 
determined by TCID50. The dotted line represents the detection limit of the assay 782 
with error bars representing the SEM. Single step growth curve analysis of 783 
m53SupA replication in comparison to the WT MNV. RAW264.7 cells were 784 
infected at a multiplicity of infection of 4 TCID50 per cell and samples harvest at 785 
the indicated time post infection. Infectious virus was released by freeze-thaw 786 
and titrated. Infectious virus titres are shown in panel B, protein expression levels 787 
of NS7 and VP1 in Panel C and viral genomic RNA levels in panel D. In panel D 788 
only samples from the exponential growth phase are shown. Error bars represent 789 
the SEM. 790 
 791 
Fig. 4: Sequence changes at position 4922 can compensate a defect in 792 
Sla5045. 793 
A) Schematic illustration of the region of the MNV genome mutated in m53 and 794 
m53SupA. The sequence of the region shown is represented in the positive 795 
polarity to highlight the NS7 reading frame with the negative polarity sequence 796 
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shown below. The amino acids encoded by the region are highlighted, as well as 797 
the position of the SupA mutation (in italics) and the mutations introduced in m53. 798 
B) Virus yield following reverse genetics rescue of cDNA constructs containing 799 
with wild-type (WT) or m53 MNV cDNA with various changes at position 4922. 800 
Note that the nucleotide sequences shown represent the sequence of the anti-801 
sense RNA genome with G representing the previously isolated SupA 802 
suppressor mutation and A representing the nucleotide present in the wild-type 803 
cDNA construct. Reverse genetics recovery was performed as described in the 804 
materials and methods then the virus yield at 24 hours post transfection 805 
determined by TCID50. The dotted line represents the detection limit of the assay 806 
with error bars representing the SEM.  807 
 808 
Fig. 5: Duplication of Sla5045 enables mutagenesis in a non-coding context 809 
A) Schematic illustration of the reconstruction of Sla5045Dup stem-loop 810 
duplication constructs. The position of the authentic Sla5045 on the anti-sense 811 
RNA genome is shown and the introduced additional Sla5045 shown as Sla2. 812 
For simplicity, only wild-type copies of the stem-loop are shown. The positions of 813 
the NS7 stop and VP1 start codons on the corresponding positive sense viral 814 
RNA are also shown for reference. B) Virus yield following reverse genetics 815 
rescue of capped in vitro transcribed RNA of wild type (WT), polymerase frame-816 
shift (POLFS), m53 or Sla5045 stem-loop duplication  (Sla5045Dup) constructs. 817 
The Sla5045Dup constructs are shown using the nomenclature copy1/copy2 as 818 
described in the text. Reverse genetics recovery was performed as described in 819 
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the materials and methods using in vitro transcribed, enzymatically capped RNA 820 
and the virus yield at 24 hours post transfection determined by TCID50. A 821 
western blot analysis for NS7 expression is shown below the virus yield data. 822 
The asterisk indicates a greater than full length NS7 product observed in cells 823 
transfected with SLa5045Dup WT/WT. C) Virus yield assay following a single 824 
passage of virus recovered following RNA transfection of wild type MNV (WT) or 825 
various Sla5045 stem-loop duplications. The dotted line represents the detection 826 
limit of the assay with error bars representing the SEM. D) 5’RACE analysis of 827 
WT MNV or Sla5045 stem-loop duplications. Viral RNA was isolated from 828 
infected cells and subjected to 5’ RACE analysis. Samples were prepared with or 829 
without reverse transcription (RT) and then subjected to PCR as described in the 830 
materials and methods. The wild-type MNV virus was included as a control. 831 
Samples were then sequenced and aligned as shown. The lower case polyG 832 
tract is introduced as a result of the 5’ RACE methodology. 833 
 834 
Fig. 6. Mutational analysis of Sla5045 in a non-coding context. 835 
A) Schematic illustration of Sla5045 mutants characterized in the Sla5045Dup 836 
cDNA backbone. The Sla5045 is shown in the 3’-5’ direction with the site of 837 
subgenomic RNA initiation shown in italics. Mutations introduced are highlighted 838 
in bold. B) Virus yield following reverse genetics rescue of capped in vitro 839 
transcribed RNA of WT, polymerase frame-shift (POLFS), m53 or Sla5045 stem-840 
loop duplication (Sla5045Dup) constructs. The Sla5045Dup constructs are 841 
shown using the nomenclature copy1/copy2 as described in the text. Reverse 842 
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genetics recovery was performed as described in the materials and methods 843 
using in vitro transcribed, enzymatically capped RNA and the virus yield at 24 844 
hours post transfection determined by TCID50. C) Virus yield assay following a 845 
single passage of virus recovered following RNA transfection the various 846 
Sla5045 stem-loop duplications. The dotted line represents the detection limit of 847 
the assay with error bars representing the SEM 848 
 849 
Fig. 7: Sla5045 can direct for the initiation of RNA synthesis by the MNV 850 
RdRp in vitro.  851 
A) Recombinant RdRps from MNV and the human GII.4 norovirus used in this 852 
study. The RdRps was expressed and purified as described in the materials and 853 
methods. The gel images were from SDS-PAGE stained with Coomassie Blue. 854 
B) Schematics of the synthetic MNV proscript, MNVps, and the GII.4 RNA 855 
proscript, GII.4Ps, used for the in vitro RNA synthesis assays. The initiation 856 
nucleotide used to initiate MNV subgenomic RNA synthesis is in bold and 857 
denoted with a bent arrow. A proscript containing a mutated initiation site named 858 
IM is used to control for specificity. C) Denaturing PAGE analysis of in vitro RNA 859 
synthesis assays containing the MNV NS7 with either MNVps or the initiation 860 
mutant (IM). The positions of primer extension (PE) and de novo (DN) initiation 861 
products are highlighted with arrows. The lengths of the RNAs were assigned by 862 
comparison to RNAs of 8 to 51-nt that were labeled at the 5’ terminus with a 32P. 863 
D) Virus genotype-specific RdRp-proscript interaction results in higher level of 864 
 37
RNA-dependent RNA synthesis. The results are representative of six 865 
independent experiments.  866 
 867 
Fig. 8: Negative-sense subgenomic RNA is produced during MNV 868 
replication. A) Northern blot analysis of RNA isolated from either mock infected 869 
(mock) or MNV infected (Inf) cells. 1.5μg of RNA harvested 10 hours post 870 
infection of cells with a multiplicity of infection of 5 TCID50 per cell, was 871 
denatured by glyoxylation prior to agarose gel electrophoresis. Positive and 872 
negative-sense RNA was detected using strand specific RNA probes as 873 
described in materials and methods. Control in vitro transcribed RNAs were 874 
generated representing the positive- (+) or negative-sense (-) viral RNAs were 875 
used as a control. B). Quantitative real-time PCR analysis of the RNA sample 876 
shown in panel A. The RNA was analyzed using a strand-specific RT-qPCR 877 
assay designed to detect only the genomic RNA or both genomic and 878 
subgenomic RNAs simultaneously. The genome copy number is shown as 879 
genome equivalent per 25ng of total RNA and was determined by comparison to 880 
in vitro transcribed control RNAs. The data show was represent the mean and 881 
standard deviation of 4 independent repeats. 882 
 883 

Virus Nucleotide position within Sla5045 Changes
outside of
Sla5045
5018 5021 5024 5039 5042 5045
WT A A C G U U
m53 G G U G U U
Rev1 G G U G C U G4910A
Rev2 A G U G U U
Rev3 A G U G U U G4859A
Rev4 A G U G U U U4967C
Rev5 G G C G U U
Rev6 G G C G U U U4967C
Rev7 G G U A U U
Rev8 A A C G U U
Rev9 G A U G U U
SupA G G U G U U A4922G
SupB G G U G U U U4914C*
SupC G G U G U U U4967C
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